Priming for Expansion, GreenStar Strikes a Deal with Progressive Herbs
October 10th, 2019
App, Exclusive, News, Top News
GreenStar Biosciences Corp. (CSE: GSTR) already had a strong cannabis market presence through its stake in Cowlitz County Cannabis Cultivation, a leading player in Washington State. Primed for expansion, GreenStar has struck a deal with Progressive Herbs Inc., forging a new joint venture that should make all involved even stronger.
The new JV between GreenStar and Progressive, called Capri PHGS LLC, was kicked off with a pilot cultivation evaluation of a new, proprietary growing system owned by Progressive and its affiliate Aggressively Organic, Inc.
The initial study of the growing system showed the technology can produce cannabis plants that have much higher levels of cannabinoids than similar strains on the market today, along with several other important benefits for cannabis operators.
Capri JV Partnership
Vancouver-based GreenStar and Indiana-based Progressive are 50/50 owners in Capri. Per the deal, the JV has exclusive rights to utilize the proprietary cultivation technology for a sustainable, inexpensive growing system known as Micro Dendritic Pods™. The strategy is for Capri to develop, manufacture, commercialize and sell products grown with the Micro Dendritic Pods technology for sales globally in the cannabis, hemp, medical and biopharmaceuticals markets.
The two companies and their affiliates have an opportunity to leverage their individual successes.
Cowlitz’s products, including pre-rolls, flower (cannabis buds), BHO (butane hash oil) waxes, vaporizer cartridges and crystallines, are found on the shelves of more than 80 retail stores in Washington State. Cowlitz is Washington’s largest independent buyer of dried flower and producer of more than 2,000,000 pre-rolls annually.
There are different synergies in play here between Cowlitz and Capri that can be profitable for all parties considering GreenStar owns certain assets of Cowlitz, including IP and property leases. The details have yet to be fleshed out, but Cowlitz could become a buyer from Capri, licensee of the technology or some combination in a future deal that ensures production of high-quality, low-cost cannabis products.
Judging from initial testing, it looks like GreenStar and Progressive are onto something with the Micro Dendritic Pods.
Cannabinoids are components of the cannabis plant that act upon the body’s endocannabinoid system. The two most famous are CBD and THC (tetrahydrocannabinol), but there are more than 100 others that have various effects on the body. Notably, THC is the cannabinoid responsible to the psychoactive high commonly associated with ingesting marijuana. CBD, which also can be derived from hemp – defined as cannabis sativa with less than 0.3% THC – has zero psychotropic effect.
CBD is the cannabinoid frequently heralded for a bevy of positive therapeutic effects in treating everything from dry skin to anxiety to epileptic seizures. CBD derived from hemp became legal throughout the U.S. this year with the passage of the 2018 Farm Bill.
One of the first initiatives for Capri was to complete a cultivation test using the new technology for cannabinoid analysis. In doing so, about 2,500 plants spanning three different cannabis strains were grown at Cowlitz’s facilities in Washington. The data was compelling, to say the least.
Results from independent lab tests showed total cannabinoid percentages between 22.85% to 32.54%, depending on the strain. To add some context, industry averages are generally 15%-23% for similar strains.
The strains were diverse. One had high THC content (24.54%) and lower CBD (2.24%). Another had high CBD (22.85%) and lower THC (9.78%), while the third was virtually CBD-free (<0.01%) with high THC (25.88%).
It Doesn’t Get Any Easier Than This
In addition to a superior cannabinoid profile, the cultivation technology further demonstrated other efficiencies and benefits compared to conventional greenhouse operations. The company didn’t give away the “secret sauce,” but it did say that cultivation room was completed using “off-the-shelf” environmental control products, meaning no expensive special equipment is necessary.
This is possible, as confirmed by Washington State accredited testing facility Praxis Laboratory, without the use of pesticides, herbicides or fungicides. Moreover, Medicine Creek Analytics, a Washington State accredited heavy metal screening lab, confirmed no detectable levels of the heavy metals arsenic, lead, cadmium or mercury in the plants from the pilot run.
A drilled down look at the economics showed that electricity costs could be chopped in half, as measured by about 3 grams of plant produced from one watt of electricity versus 1-1.5 grams per watt for today’s technology.
What’s better than a cannabinoid-loaded, contaminant-free plant produced at lower operating cost per square foot? One that grows faster. All three plant strains were harvested in 72 days, which equates to up to five harvest cycles per year. This compares to an average of three or four harvests annually for a traditional indoor grow facility.
“We believe we have proven the proof of concept effectiveness of this technology. We are excited to continue pursuing further testing and leveraging this proprietary technology,” said GreenStar CEO Rahim Rajwani, in a press release on the pilot testing.
The go-forward strategy involves scaling cultivation operations with the proprietary technology to lend further validation to its benefits. Capri will then use the technology for low-cost indoor production for itself and look to build an additional revenue channel through a licensing model to allow other producers, presumably including Cowlitz, access to Micro Dendritic Pods™.
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.